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Uncontrolled hemorrhaging, or blood loss, accounts for upwards of 3 million 
deaths each year and is the leading cause of preventable deaths after hospital 
admission around the world.  Biological-based hemostatics are quite effective at 
controlling blood loss, but prohibitively expensive for people in developing countries 
where over 90 % of these deaths are occurring.  Synthetic-based hemostatics are less 
expensive, yet not nearly as effective as their biological counterparts.  A better 
understanding of how synthetic materials interact with and affect the body’s natural 
clotting response is vital to the development of future hemostatic material technology 
which will help millions around the world. 
Initial in vitro experimentation focused on investigating the key chemical and 
structural material properties which affect Factor VII (FVII) activation in citrated 
human plasma.  Enzyme-linked assays were utilized to confirm the ability of 
  
specifically formulated charged hydrogels to induce FVII activation and provided 
insight into the critical material parameters involved in this activation.  Dynamic 
mechanical analysis was used to establish a correlation between polymeric 
microstructure and FVII activation.  Experiments utilizing coagulation factor depleted 
and inhibited plasmas indicated that FVII, FX, FII, and FI are all vital to the process 
outlining the general mechanism of fibrin formation from the onset of FVII 
activation.  The ability of the polymer to induce fibrin formation in “artificial plasma” 
explicitly lacking calcium, TF, and platelets suggested that a specifically designed 
material surface has the capability to substitute for these vital cofactors.   
Clinical diagnostic experimentation using sheep blood indicated that hydrogels 
containing higher amounts of electrostatic positive charge and lower cross-link 
density were able to induce faster, more robust clot formation in the presence of a 
coagulation cascade activator.  Subsequent in vivo animal experimentation clearly 
demonstrated the ability of such hydrogels to aggregate platelets and erythrocytes 
promoting the formation of an effective hemostatic seal at the wound site.  Moreover, 
in vivo testing confirmed the viability of such a charged polymer hydrogel to 
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1 Chapter 1: Motivation and Background 
The overarching goal of this research is a better understanding of how polymer 
hydrogel morphology, mechanical properties and electrostatic charge interact with 
and affect the body’s hemostatic response.  The directed goal of the research is 
translating this understanding into the development of a new polymer hydrogel-based 
material for hemorrhage control.    
 
1.1 Research Motivation 
Traumatic injury is the leading cause of death worldwide for persons between the 
ages of 5 and 44, accounting for over 5,000,000 deaths each year
4
.  Uncontrolled 
hemorrhaging, or blood loss, accounts for 30 % to 40 % of these deaths and is the 
leading cause of preventable deaths after hospital admission.  Moreover, on the 
battlefield an astounding 90 % of deaths occur before soldiers reach critical care, 
mainly due to blood loss
2-4
.  Furthermore, there are over 500,000 people around the 
world living with potentially lethal clotting disorders such as hemophilia.   
There are two main categories of hemostatic materials used to control 
hemorrhaging:  biological-based and synthetic.  Biological-based hemostatics, which 
contain animal derived or purified human clotting substrates such as thrombin or 
fibrin, are quite effective at controlling blood loss but carry serious disease 
transmission risks and are prohibitively expensive for people in developing countries 
where over 90 % of these deaths are occurring
5
.  Synthetic-based hemostatics are less 




controlling blood loss.  It is only through a better understanding of how materials 
interact with the body’s hemostatic response will we as engineers be able to design 
materials capable of safely and effectively amplifying this response to control life 
threatening blood loss. The advancement of hemostatic technology, and the 
development of an inexpensive and effective material capable of rapidly stopping 
blood loss, has the potential to save millions of lives each year.   
 
1.2 In Vivo Hemostasis 
The body’s hemostatic response to control blood loss involves two distinct 
processes: a primary response involving the formation of a platelet-based seal at the 
wound site, and a secondary response which involves the activation of the 
coagulation cascade resulting in the stabilization of this platelet plug by fibrin.  The 
initial stage in the primary hemostatic response is marked by the adhesion and 
deposition of platelets to collagen within the subendothelium layer of the wound site.  
The adhesion of platelets to the injured vessel wall is mediated by the binding of von 
Willebrand Factor (vWF) to several distinct platelet glycoprotein receptors, most 
notably Ib-V-IX and integrin αIIBβ3
6
.  Besides glycoprotein Ib, there are several other 
immunoglobulin collagen receptors on the platelet surface which are also capable of 
providing tethering to the subendothelium at the wound site, including glycoproteins 
Ia/Ia, IV, VI, p47, and p65
7-9
.   
Binding of vWF also initiates the activation of platelets.  Initial activation of 
platelets causes them to transform in shape from smooth discoids to “spiny” spheroids 




contents of their main storage units; α-granules which contain thrombospondin, 
fibrinogen, fibronectin, platelet factor 4, vWF, platelet-derived growth factor, β-
thromboglobulin, Factor V (FV), and FVIII, along with dense bodies which contain 
adenosine diphosphate (ADP), adenosine triphosphate (ATP), and serotonin10.  These 
molecules are key to initiating further platelet activation and aggregation resulting in 
the formation a hemostatic platelet plug at the wound site.  Platelet activation also 
induces the exposure of negatively charged surfaces on platelet membranes which 
facilitate the activation of the coagulation pathway. Activation of the coagulation 
pathway results in the generation of fibrin which stabilizes initial platelet plug 
formation (secondary hemostasis).  The rapid generation of fibrin at the wound site is 
crucial to stabilizing the initial platelet plug to control hemorrhaging.   
 
1.2.1 Blood Coagulation Cascade  
The blood coagulation cascade is a remarkably complex biological process which 
has evolved over millions of years.  This evolution has led to the development of an 
incredibly intricate yet coordinated system consisting of various components which 
interact in incredibly specific ways to yield a single final product; fibrin.  The 
evolutionary complexity of the system is simultaneously its greatest strength, 
allowing for feedback regulation on a multitude of levels, and its greatest weakness, 
introducing more proverbial links in the chain which may ultimately fail.  Yet it was 
through the discoveries of these supposed weak links which has led to most of our 
modern understanding of the functioning of the blood coagulation cascade.  In 1936 




necessary for proper clotting, which was later termed factor VIII (FVIII)
11
.  The study 
of individuals with deficiencies in their clotting mechanism led to the discoveries of 















.  It is mainly through these discoveries that have led to the modern day 
understanding of the blood coagulation cascade, yet it apparent from the recent 
discoveries that this understanding is far from complete. 
The blood coagulation cascade involves a series or “cascade” of zymogen 
activation reactions.  At each stage a precursor protein (zymogen) is converted to an 
active protease by cleavage of one or more peptide bonds in the precursor molecule.  
The coagulation cascade consists of two pathways: the contact activation pathway, 
and the tissue factor pathway which lead to the ultimate activation of the final 
common pathway.  The activation of the contact activation pathway, formerly known 
as the intrinsic pathway, involves the mutual coordination of 4 key proteins which 
form what is known as the contact complex and consists of FXII, FXI, high molecular 
weight kininogen (HMWK) and prekallikrein (PK).  It is the association of these 
proteins, in contact with an anionic surface, which leads to the activation FXII and 
corresponding contact pathway activation.  PK, the zymogen of kallikrein, has the 
capability of inducing the direct activation of FXII and is also involved in the 
association of HMWK within the contact complex.  HMWK is the main cofactor of 
the complex and contains binding sites for PK, FXI, and calcium along with a domain 
which is capable of interacting with hydrophilic and anionic surfaces
21-23
.   The role 
of HMWK in the contact activation pathway is related to its ability to coordinate the 
FXI-PK-FXII complex together resulting in the activation of FXII
24




(FXIIa) is able to directly activate FXI (FXIa) in the presence of HMWK which in 
turn is able to activate FIX (FIXa), an event in which calcium and platelets, or rather 
a phospholipid surface are primary cofactors.  FIXa combines with its primary 
cofactor activated FVIII (FVIIIa) to form a membrane (phospholipid)-bound complex 









Research has recently shown that the tissue factor pathway is the primary pathway 
of fibrin formation, while the contact activation pathway acts primarily as an 
amplifier of cascade activation and fibrin generation
27,28
.  The activation and 
sustainment of the tissue factor pathway involves the coordination of a multitude of 
proteins and cofactors including FVII, calcium, tissue factor pathway inhibitor 
(TFPI), tissue factor (TF), and a phospholipid surface.  Human coagulation FVII is a 
single chain, glycoprotein which circulates in normal human blood and is the main 
activator of the tissue factor pathway
29,30




in a structural change which activates the zymogen transforming it into a potent 
vitamin K-dependent serine protease.  This structural change also allows for the 
protein to effectively bind to its cofactor, TF.  The distribution of TF is carefully 
coordinated in a hemostatic layer, with the ability to induce coagulation upon the 
disruption of the vascular endothelium
31-35
.  TF forms a stable complex with FVIIa, 
and this complex is capable of directly initiating the common coagulation pathway 
via the activation of FX or indirectly through the activation of FIX which in turn is 
able to activate FX
36
.  TF is most effective as a procoagulant when incorporated into 
phospholipid membranes, a surface which is typically provided by platelets
37-39
.  
Calcium has been shown to play a key role as a cofactor in the generation and 
activity of several vitamin K-dependant serine protease coagulation factors, including 
FVIIa
40,41
.  A high-affinity calcium binding site in the protease domain of FVII has 
been shown to mediate the interaction between TF and FVIIa
41,42
.  Conversely, the γ-
carboxyglutamic acid (Gla) domain of FVIIa contains several low affinity calcium 
binding moieties which aid in the interaction of FVIIa and phospholipid surfaces
43
.  
In most instances, calcium binding leads to a necessary conformation change which 
allows these factors to effectively “dock” on a surface and exhibit their cleavage site.  
Without the binding of calcium, in calcium depleted medium, it is believed that this 
Gla domain slightly unfolds exposing a highly negatively charged domain to the 
media which is capable of interacting with a positively charged surface.  Although 
groups have shown the capability of FVII to bind to such positively charged surfaces 
in calcium depleted environments, such as citrated plasma, the mechanism by which 




understood.  TFPI is the main inhibitor of the FVIIa-TF complex, and is an important 
feedback regulator  of tissue factor pathway activation
44,45











The activation of FX by either FIXa or the FVIIa-TF is the initial step in the 
activation of the final common pathway.  Immediately after activation FXa 
complexes with FVa to form a complex, known as the prothrombinase complex, 
which is capable of converting the zymogen prothrombrin (FII) to its enzymatic 
analogue thrombin (FIIa).  The ability of this prothrombinase complex to convert 
prothrombin to thrombin is highly dependent on both calcium and a phospholipid 
surface, which is typically provided by platelets. Thrombin catalyzes a multitude of 




along with directing the disassociation of FVIII from vWF, and the conversion of 
fibrinogen to fibrin.  Although the initial amount of thrombin formation is unable to 
produce a sufficient amount of fibrin to stabilize the formed platelet plug, the 
reactions it sets in place in combination with the sustained activation of FX lead to a 
subsequent thrombin burst which results in substantial fibrin formation
46
.  Fibrin 
strands form spontaneously after conversion, which are subsequently cross-linked by 
FXIIIa resulting in a matrix which entrap platelets and erythrocytes (red blood cells) 
to produce a stabilized hemostatic plug at the wound site (Figure 1.3).   
Figure 1.3:  Scanning electron micrograph of a blood clot consisting of platelets and erythrocytes  (red 




1.3 Hemostatic Technology and Product Review 
 
  The field of hemostatic agents and materials has expanded dramatically within 




around $700 million and is expected to reach $1.5 billion by 2015.  This considerable 
expansion and evolution of the field throughout the last century has also been 
accompanied by tremendous diversification resulting in a multitude of hemostatic 
products now available on the market, each with their own advantages and 
disadvantages.   
The hemostatic products available on the market today are either biological-based 
or synthetic.  Biological-based hemostatics are defined as any hemostatic agent 
comprised of animal or “animal derived” substrates.  These types of hemostatic 
agents typically work by initiating, amplifying, or assisting the natural coagulation 
system.  Although they have excellent hemostatic effects and work via the promotion 
of the body’s natural responses, they are incredibly expensive (up to $500 per 
application) and carry risks of disease infection and severe immunological response.  
Synthetic hemosatic agents are typically less expensive yet often fail to effectively 
induce hemostasis and are mainly designed to be scaffolds for coagulation to occur.  
Furthermore, most biological and synthetic hemostatic materials are dependent on 
clotting platelets to achieve their effect, making them ineffective with patients with 
platelet deficiencies, such as thrombocytopenia.  Additionally, there are virtually no 
hemostatic agents with the capability of delivering therapeutics in a controlled and 
efficient manner. 
 
1.3.1 Biological-Based Hemostatics 
 
Biological-based hemostatic agents contain, incorporate, or are derived from 




into the type of biological substrates incorporated into the system including collagen, 
thrombin, fibrin, albumin, and/or platelets.    
 
1.3.1.1 Collagen  
Collagen is the main protein of connective tissue in mammals, including the skin, 
bones, ligaments, and tendons making up about 30 % of the total protein in the 
body
47
.  In addition to providing structural integrity for the animal body, including all 
organs, collagen also facilitates the activation of the coagulation cascade.  Collagen’s 
ability to facilitate coagulation, along with the fact that it is naturally occurring, 
makes it an ideal choice for a hemostatic agent.  Collagen is typically incorporated 
into the products via gelatin or microfibrillar form.  Gelatin is an irreversibly 
hydrolyzed form of collagen and may be prepared as a powder, sponge, sheet, film or 
foam.  Gelatin products are typically pliable, easy to handle, and relatively inert.  
When placed in soft tissue gelatin products typically absorb in 4 to 6 weeks, yet when 
applied to bleeding nasal, rectal or vaginal mucosa, will liquefy in approximately 2 to 
5 days.  The product Gelfoam (Pfizer, New York, NY), first introduced in 1945, is 
produced from purified pork skin gelatin granules.  Effects appear to be more 
physical than the result of altering the blood clotting mechanism.  The foam swells up 
to 45 times its original dry weight and 200 % of its initial volume.   
Microfibrillar collagen is the predominant form used in modern hemostatic 
products.   The collagen network acts as a framework which aggregates clotting 
factors, platelets, along with various coagulative and adhesive proteins to facilitate 




powder (shredded fibrils), sheets, and sponges.  Market examples include Ultrafoam 
(Davol Inc., Cranston, RI), Avitene (Davol Inc., Cranston, RI), Instat (Johnson & 
Johnson, Langhorne, PA), Helistat and Helitene (Integra LifeSciences, Plainsboro, 
NJ), Collatape/CollaCote/CollaPlug (Integra Lifesciences Corporation, Plainsboro, 
NJ), Collastat and Collatene (Xemax, Napa, CA)
48
.  
Collagen-based hemostatic products are easily removable, cause little aggravation 
to the wound site, and can be very effective at controlling hemorrhaging (especially 
relative to cellulose or gelatin-based  hemostatics)
48
.  Disadvantages of collagen-
based products include their high price (around $150 per dressing), poor 
biodegradability, inherent risk of antigenicity, low solubility (difficult to make 
concentrated solutions), and handling difficulties since the products will irreversibly 





Thrombin is the central activating enzyme of the common coagulation pathway.  
Thrombin circulates within blood in its precursor (zymogen) form, prothrombin.  
Prothrombin is specifically cleaved to produce the enzyme thrombin.  The main role 
of thrombin in the coagulation pathway is to convert fibrinogen into fibrin, which in 
turn is covalently cross-linked to produce a hemostatic plug.  Thrombin products are 
typically sold in liquid or powder form and include Thrombostat (Parke-Davis, Ann 
Arbor, MI), Thrombin-JMI (King Pharmaceuticals, Briston, TN), and Quixil (Omrix 
Biopharmaceuticals Ltd, Tel Hashomer, Israel).  There are also several combination 




combination of thrombin and fibrin used mainly as a tissue sealant, along with 
FloSeal and SurgiFlow (Baxter Healthcare Corporation, Westlake Village, CA) 




Thrombin products take advantage of the natural physiologic coagulation 
response by augmenting, amplifying, and assisting the process.  Advantages of 
thrombin-based products include low risk of foreign body or inflammatory reactions, 
firm attachment to wound bed, and its excellent hemostatic effect, specifically with 
patients that have platelet dysfunctions
50
.  Another advantage of thrombin is the 
versatility that the product may be applied, in powder or liquid (spray on) form.  
Disadvantages of these products include their often prohibitive high price ($75 - $500 
per application), difficulty of use including the inconvenience of premixing 





1.3.1.3   Fibrin 
 
Fibrin is a fibrillar protein which is polymerized and cross-linked to form a mesh 
network, typically at the site of an injury after the induction of the coagulation 
cascade.  The mesh network, incorporative of other various proteins and platelets, 
forms a hemostatic plug to prevent continuous or further blood loss
51
.  Fibrin is 
converted from fibrinogen by thrombin.  Fibrin is in turn polymerized and covalently 
cross-linked by FXIIIa
52
.  Due to its natural mechanical hemostatic role fibrin has 
been commercially used to control blood flow since the early 1900s
53




glues or fibrin sealants are derived from human and bovine tissue.  The product is 
typically sold in a dual syringe.  The first syringe compartment contains the matrix 
and matrix stabilizing components including fibrinogen, FXIII, fibronectin, and 
fibrinolysis inhibitors.  The second syringe compartment contains the activating 
agent, typically thrombin and calcium chloride.  At the time of application, the 
contents of both syringes are ejected, combining to activate fibrin matrix formation 
which typically takes a matter of seconds to set and approximately 5 to 10 days to 
degrade or absorb into the body.  Various fibrin sealants on the market include Tiseel 
(Baxter HealthCare Corporation, Westlake Village, CA), FibRx (CryoLife Inc., 
Kennesaw, GA), Crosseel (Johnson & Johnson, Langhorne, PA), Hemaseel 
(Haemacure Corporation, Montreal, Quebec), Beriplast P (Aventis Behring, King of 
Prussia, PA), and Bolheal (Kaketsuken, Kumamoto, Japan)
48
.  
Fibrin-based hemostatics or tissue sealants are fast acting, composed of native 
coagulative factors, are biodegradable, do not promote inflammation or tissue 
necrosis, have diverse applications, and are particularly useful in patients with 
coagulation deficiencies such as hemophilia or von Willebrand’s disease.  Major 
disadvantages of these products include their often prohibitive price ($100 - 




1.3.1.4   Other Biological-Based Hemostatics 
Other prominent biological-based hemostatic products include those composed  of 
covalently cross-linked protein networks such as BioGlue (Cryolife, Kennewsaw, 




Vitagel (Orthovita, Malvern, PA).  BioGlue is comprised of bovine serum albumin, 
and various other proteins, cross-linked with glutaraldehyde to form a rigid, insoluble 
matrix.  The reaction occurs spontaneously upon the introduction of glutaraldehyde to 
the protein mixture, and requires no external factors such as coagulation factors
55
.  
Disadvantages of these products include their high price ($300 - $425/ml application), 
mediocre hemostatic effect
56
, necessity of a dry environment for application
55
, the 
toxic effects associated with tissue exposure to glutaraldehyde
57
, and risk of immune 
reactions associated with glutaraldhyde-based products
58
.  
Costasis is a combination product combining bovine collagen and the patient’s 
own platelets.  The collagen within the product promotes fibrin-induced hemostasis 
on its network
48,59
.  The presence of platelets in such a product improves overall clot 
strength and supplies various growth factors which facilitate tissue regeneration.  




1.3.2 Synthetic Hemostatics 
Non biological-based, or synthetic, hemostatic agents are defined as any product 
which does not incorporate biological materials, or more specifically animal derived 
components.  Synthetic hemostatics are typically cheaper, easier to use, and easier to 
apply relative to their biological counterparts.  Furthermore, synthetic hemostatics 
have no innate antigenicity, rarely induce immune responses or inflammatory 
reactions, and are inherently free of disease vectors
60
.  The main classes of synthetic 
hemostatic include cyanoacrylates, polysaccharides (e.g. oxidized cellulose, N-acetyl 




1.3.2.1  Cyanoacrylates 
 
Cyanoacrylates are liquids that rapidly polymerize.  These products create a tight 
seal between tissues, obstructing blood flow.  Cyanoacrylates are categorized upon 
their length.  Shorter chain cyanoacrylates (ethyl cyanoacrylates) are typically quicker 
to absorb yet more toxic relative to intermediate (butyl cyanoacrylates) or longer 
chain cyanoacrylates (octyl cyanoacrylates)
61
.  Due to their inherent high toxicity few 
hemostatic products composed of short chain cyanoacrylates have reached the 
market.  There is however some research supporting the efficacy of Krazy Glue 
(ethyl-2-cyanoacrylate, Elmer’s, Columbus, OH) for cutaneous wound closure
62
.  
Cohera Medical Corporation is currently in the process of developing a butyl 
cyanoacrylate (isobutyl-2-cyanoacrylate), marketed as TissuGlu (Cohera Medical 
Inc., Pittsburgh, PA).  Furthermore, there are several octyl acrylate-based hemostatic 
products that are FDA-approved for skin closure which include Dermabond (Ethicon, 
Somerville, NJ) and Band-Aid Liquid Bandage (Johnson & Johnson, Langhore, PA). 
Cyanoacrylates are typically nonreactive, do not promote infection, rapidly 
curing, and are only moderately expensive
48
.  Disadvantages of cyanoacrylates and 
cyanoacrylate-based hemostatics include difficulty of application due to their highly 





1.3.2.2   Polysaccharides 
 
The two main polysaccharides used as hemostatics today are oxidized cellulose 




specifically oxidized cellulose and N-acetyl glucosamine, have been known since the 
early twentieth century.  Oxidized cellulose is derived from plant fiber, which is in 
turn oxidized in the presence of nitrogen dioxide to form cellulosic acid
63
.  Oxidized 
cellulose has been shown to accelerate thrombin generation within the body
64
. 
Furthermore, the polysaccharide meshwork serves as a physical framework for 
coagulation to occur, with moderate absorbent properties
50
.  Oxidized cellulose 
products on the market today include Oxycel (Becton Dickinson, Franklin Lakes, NJ), 
Celox (Medtrade Products Ltd., Crewe, England), Surgicel (Johnson & Johnson, 
Langhorne, PA), and BloodStop (LifeScience PLUS, Inc., Santa Clara, CA). 
Cellulose-based hemostatics are relatively easy to handle, fully absorbable and 
biodegradable (over 1 to 6 weeks), relatively inexpensive, and have antibacterial 
properties
65
.  The major drawback of these products is the risk of foreign body 
reactions
66,67
.   Furthermore, these products have only moderate hemostatic capability 
and therefore are reserved as an adjunct to the body’s natural clotting response rather 
than a synthetic replacement.  
Poly-N-acetyl glucosamine, also known as chitin or chitosan, is a complex 
polysaccharide produced by fermenting microalgal cultures.  The hemostatic effects 
of poly-N-acetyl glucosamine are believed to be a result of the attraction and binding 
of circulating blood cells
68
.  The positive charges on the polymer attract the 
negatively charged erythrocytes to help seal the clot.  Poly-N-acetyl glucosamine also 
induces vasospasm effects which aid in hemostasis
68
.  Poly-N-acetyl glucosamine 
products include HemCon (HemCon Inc., Portland, OR), TraumaDex (Medafor, 




Clo-Sur P.A.D. (Scion Cardio-Vascular, Miami, FL), and Chito-Seal (Abbott 
Vascular Devices, Redwood, City, CA)
48
.  
Advantages of poly-N-acetyl glucosamine dressings include their ease of 
application, robustness, and lack of toxicity.  Disadvantages include the high cost 




1.3.2.3  Synthetic Polymers 
 
Most polymer-based hemostatics are designed to provide a mechanical tissue 
sealant.  The majority of products on the market today are composed of polyethylene 
glycol (PEG) which are applied and polymerized at the wound site. The polymer is 
typically cross-linked with itself or with a primer to yield a robust framework 
stopping blow flow and sealing tissue.  Most PEG products undergo biodegradation 
in approximately 30 days.  PEG products include Coseal (Baxter Healthcare 
Corporation, Westlake Village, CA) and AdvaSeal-S (Genzyme Corporation, 
Cambridge, MA).  PEG-based hemostatics or tissue sealants are typically non- 
inflammatory, do not induce immune response, and are biodegradable.  Drawbacks 
include difficulty of application and high price ($200/application). 
 Pro QR Powder (Biolife, Sarasota, FL) is another polymer-based hemostatic on 
the market today.  Pro QR is a combination product of a hydrophilic polymer and a 
potassium iron oxyacid salt.  The polymer is absorptive of blood flow, promoting the 
formation of a natural blood clot while the potassium salt component releases iron 
which complexes with proteins and activates hemostatic channels
48,69




inexpensive, nontoxic, easily stored, flexible, stops bleeding rapidly, and is available 




1.3.2.4  Mineral/Metal 
 
The final class of non-biological, or synthetic, hemostatics includes those which 
incorporate metal salts or minerals such as zinc, iron, silver nitrate, or aluminum 
chloride.  Although this class of hemostatics are typically easy to use, cost-effective, 
and provide adequate hemostatic effects their toxic side effects limit their appeal. 
 Zinc paste was first used to fix tissue after surgery in the early 1940s.  Zinc paste 
solutions have impressive hemostatic abilities but are rarely used do to their harmful 
side effects including pain and toxicity at the site
50
.  Monsel’s solution is a 20 % 
ferric subsulfate solution, which is believed to occlude vessels via protein 
precipitation.  Monsel’s solution is easy to obtain, cost-effective, and resistant to 
bacterial contamination.  Major disadvantages include its caustic and toxic nature 
which may promote melanocyte activity, increased erythema, dermal fibrosis, and 
reepithelialization
70,71
. Silver nitrate is typically used as a 10 % solution and 
coagulates blood through protein precipitation.  Silver nitrate is cost-effective, easy to 
use, and has potent antibacterial properties.  Disadvantages include its severe tissue 
toxicity, risk of permanent skin discoloration, and the painful burning sensation 
experienced upon application.  Aluminum chloride has modest hemostatic properties 
and is prepared in concentrations of 20 % to 40 % in water, alcohol, ether, or 
glycerol.  Its mechanism of action is thought to be caused by the hydrolysis of the 




and can assist in the activation of the tissue factor, or extrinsic, coagulation 
pathway
50,48
.  Aluminum chloride is cost effective, easy to use, and may be stored at 
room temperature.  Side effects of its use include painful paresthesia, tissue irritation, 
and reepithelialization.  Aluminum chloride solutions are marketed as Drysol and 
Xerac AC (person-Covey, Dallas, TX)
48
.  
A small subclass of hemostatics is based upon various mixtures of minerals.  
Zeolite is a granular mixture of silicon, aluminum, sodium, and magnesium derived 
from lava rock.  When coming into contact with blood the mixture absorbs water, 
concentrating platelets and coagulation factors within the wound, accelerating the 
clotting process.  Zeolites have also been shown to induce the potent activation of the 
contact activation pathway, via the activation of FXII.  QuikClot (Z-Medica, 
Wallingford, CT) is the main product which is based upon a zeolite mixture.  Zeolite 
is inexpensive, easy to manufacture, clots fairly quickly, robust under various 
conditions, and is fairly immunological inert
48
.  The main drawback of the 
formulation is the risk of thermal injury associated with use. 
 
1.4 Dissertation Outline 
 
This research has focused on a better understanding of how material properties of 
a polymer hydrogel, specifically positive electrostatic charge and mechanical 
stiffness, effect the body’s clotting response.  Initial in vitro research focused on 
investigating the key material properties which affect the activation of the coagulation 
cascade, specifically FVII, in calcium depleted plasma (Chapter 2).  Subsequent 




properties which affect primary hemostasis, i.e. platelet plug formation, in vivo 
(Chapter 3).  Live animal testing was also completed to further investigate the effect 
that electrostatic charge and mechanical stiffness has on in vivo hemostasis and also 
to determine the viability of such a polymer hydrogel to control hemorrhaging in a 
clinically relevant model.  The specific goal of this research was a better 
understanding of the interactions that occur between polymer hydrogels and the 
body’s clotting response for the directed development of an inexpensive, safe, and 






2 Chapter 2:  Investigation into the Critical 
Mechanical and Electrostatic Properties which 
Influence Factor VII Activation by Charged Polymer 




There has been considerable research into the effects of charged surfaces on the 
blood coagulation cascade.  The ability of negatively charged surfaces, such as glass 
or the mineral kaolin, to initiate the contact activation pathway via activation of FXII 
has been known for over 50 years
72,73
.  Recently, research has shown that negatively 
charged polyphosphate species are capable of enhancing fibrin clot structure
74
.  It had 
previously been discovered by Bjourn et al.
75
, that highly positively charged materials 
have the ability to activate FVII.  Later research by Pederson et al.
76
, explained the 
ability of these positively charged surfaces to activate FVII via an auto-activation 
theory.  Other research groups have shown that amine containing polymers such as 
poly(lysine) are capable of enhancing the activation of FX along with FII
76-82
.  
Although the ability of charged surfaces to induce specific coagulation factor 
activation is well known, the roles that specific material properties have in the 
activation is not well understood.  Research was conducted to help establish a better 
understanding of the effects that material properties, specifically the combination of 
electrostatic charge and mechanical rigidity, have on the ability of a synthetic 
polymer-based material to induce the activation of FVII in citrated human source 
plasma.  Plasma was chosen to investigate the activation of FVII since it does not 




complicate the analyses.  Subsequent experimentation looked to translate the results 
obtained using plasma to blood in clinical diagnostic experimentation.  
Although FVIIa therapy is quite effective at controlling various types of 
hemorrhaging, the treatment is often prohibitively expensive and carries serious 
thromboembolic risks due to its systemic exposure
83,84
.  FVIIa requires tissue factor 
(TF) in order to effectively induce the activation of FX (common pathway).  Since TF 
is only exposed in area of vascular disruption, i.e., hemorrhaging, the hemostatic 
effect of the material is confined to this area and would not have the inherent risk of 
inducing thrombus formation within the vasculature, unlike kaolin-based materials. 
Based on known dynamics of in vivo hemostasis, activation of the tissue factor 
pathway should elicit clot formation much more rapidly than products based on 
contact pathway activation, i.e., FXII activation.  Contrary to products which activate 
FXII (such as kaolin-based products), a material capable of inducing FVII activation 
does not rely on FVIII and FIX, factors which are lacking in patients suffering from 
hemophilia A and B. In a broader sense, the research aimed to establish a better 
understanding of the interactions occurring between a synthetic polymer and the 
blood coagulation cascade, which will be integral in the future development of blood 









2.2.1 Materials  
 
Acrylamide, N,N’-methylenebisacrylamide (BIS),  N,N,N’,N’-
tetramethylethylenediamine (TEMED), 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), ammonium persulfate (APS), and human fibrinogen 
(FI) were purchased from Sigma-Aldrich (Milwaukee, WI).  N-(3-
aminopropyl)methacrylamide hydrochloride (APM) was purchased from 
Polysciences (Warrington, PA).  N-(2-hydroxyethyl)methacrylamide (HEM) was 
purchased from Monomer-Polymer (Trevose, PA).  Sodium hydroxide (NaOH), 
sodium phosphate monobasic, sodium chloride (NaCl), potassium chloride (KCl), and 
hydrochloric acid (HCl) were purchased from Mallinckrodt Baker (Phillipsburg, NJ).  
Dextrose (anhydrous, ACS grade) was purchased from EMD Chemicals (Madison, 
WI).  Deionized water (DI water) was obtained using a Millipore Super-Q water 
system (Billerica, MA).  Plastic capped glass vials were purchased from VWR 
Scientific (West Chester, PA).  24-well cell culture plates were purchased from 
Corning Life Science (Corning, NY). 
Normal, human source plasma (pooled, sterile filtered, 4 % (w/v) sodium citrate) 
and factor I (FI) deficient plasma (pooled, sterile filtered, 4 % (w/v) sodium citrate) 
were purchased from Vital Products (Boynton Beach, FL).  Human FI (fibrinogen) 
was purchased from Sigma-Aldrich (Milwaukee, WI).  Human coagulation factor II 
(FII), FV, FVII, FIX, and FX were purchased from Haematologic Technologies 
(Essex Junction, VT).  All proteins were buffered in 50 % (v/v) glycerol/water.  FII 




FIX deficient plasma, FX deficient plasma, FXI deficient plasma, and FXII deficient 
plasma along with the chemical inhibitors corn trypsin inhibitor (CTI), D-
phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK), and L-glutamyl-L-
glycyl-L-arginine chloromethyl ketone (GGACK) were all purchased from 
Haematologic Technologies (Essex Junction, VT).  All factor deficient plasmas were 
prepared from citrated (4 % (w/v) sodium citrate), normal human plasma (pooled, 
sterile filtered).  Goat polyclonal primary fibrinogen antibody was purchased from 
Abcam (Cambridge, MA).  The immunogen of this antibody was fibrinogen of human 
plasma (Abcam, ab6666).  Alexa Fluor 488 labeled donkey anti-goat IgG antibody 
was purchased from Invitrogen (Carlsbad, CA).  
 
2.2.2 Hydrogel Synthesis   
 
A specific amount of either acrylamide, N,N’-methylenebisacrylamide (BIS), N-
(2-hydroxyethyl)methacrylamide (HEM), or N-(3-aminopropyl)methacrylamide 
hydrochloride (APM) was dissolved in DI water and mixed thoroughly until all 
components were completely solvated.  The solution was then titrated to a pH 
between 6.8 and 7.2 using sodium hydroxide (NaOH) and/or hydrochloric acid (HCl).  
After pH adjustment, the monomer solution was initiated by adding 20 µL/mL of a 
7.5 % (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED) solution, followed by 
adding 20 µL/mL of a 15 % (w/v) solution of ammonium persulfate (APS), for 
polymerization.  After polymerizing overnight, all polymer hydrogels were dried in a 
vacuum (85 kPa) oven at 85 
o




hydrogels were washed in approximately 325 mL of DI water for 24 hours and the 
dried, crushed particles were sieved between 75 and 250 µm. 
For dynamic mechanical analysis (DMA) 500 µL of monomer solution, 
immediately following initiation, was added to a well of a 24-well cell culture plate 




3 mL of ovine plasma (3.8 % (w/v) acid citrate dextrose) were added to a vial 
containing 100 mg of dried hydrogel (1.5 M APM, 1.5 M acrylamide, 0.3 M BIS).  
The vial was then rotated for 18 hours on a Barnstead International (Dubuque, IA) 
Labquake.   
For hematoxylin & eosin (H&E) staining sample slides were exposed to each 
stain for 90 seconds.  For immunohistochemical (IHC) staining slides were incubated 
with a primary fibrinogen antibody (200 µL, 62.5 µg/mL) for 60 minutes, followed 
by incubation with an Alexa Fluor 488-labeled donkey anti-goat IgG antibody (200 
µL, 5 µg/mL) for 60 minutes.  Micrographs were taken with a Zeiss, Hitech 
Instruments (Broomall, PA), Axiovert 40 CFL microscope, and Diagnostic 
Instruments (Sterling Heights, MI) digital camera with corresponding software.  For 
environmental scanning electron microscopy (ESEM) the coagulate complex was 






2.2.4 Dynamic FVII Activation Experiment  
 
A set of 6 acrylamide-co-APM-co-BIS hydrogel compositions was tested in this 
experiment.  The total concentration of APM and acrylamide was kept constant at 3 
M, and only the comonomer ratio (acrylamide:APM:BIS) was varied.  The HEM 
control (HEM CTRL) was composed of 1.5 M of HEM, 1.5 M of acrylamide and 0.3 
M of BIS.  The acrylamide control (Acrylamide CTRL) was composed of 3 M 
acrylamide and 0.3 M of BIS.   3.5 mL of human plasma (4 % (w/v) sodium citrate) 
were added to each vial containing 100 mg of dried, sieved hydrogel which was 
immediately rotated on a Labquake.  250 µL aliquot plasma samples were taken at 
30, 90, and 180 minutes.  All aliquoted samples were filtered with Whatman 
(Piscataway, N.J.) .22 µm Puradisc polyethersulfone membrane filters.  The aliquoted 
samples were analyzed to determine FVIIa concentration using an American 
Diagnostica (Stamford, CT) IMUBIND Factor VIIa ELISA. 
 
2.2.5 Surface Area Dependence of FVII Activation 
 
Composition C (1.5 M APM, 1.5 acrylamide, 0.3 BIS) used in the above Dynamic 
FVII Activation Experiment was used to investigate the surface area dependence of 
FVII activation.  Composition C along with the HEM CTRL (1.5 M HEM, 1.5 
acrylamide, 0.3 M BIS) were synthesized according to the above protocol, washed for 
24 hours in DI water, dried in a vacuum oven, and crushed using a mortar and pestle.  
The crushed particles were sieved to 4 different ranges; 53-150, 150-250, 250-355, 
and 355-425 μm.  3.5 mL of human plasma (4 % (w/v) sodium citrate) were added to 




on a Labquake.  250 µL aliquot plasma samples were taken at 30, 90, and 180 
minutes.  All aliquoted samples were filtered with Whatman (Piscataway, N.J.) 0.22 
µm Puradisc polyethersulfone membrane filters.  The aliquoted samples were 
analyzed to determine FVIIa concentration using an American Diagnostica 
(Stamford, CT) IMUBIND Factor VIIa ELISA. 
 
2.2.6 Optimization   
 
156 different polymer hydrogels, varying in monomer composition, were 
prepared for the optimization experiment.  1.11 mL of human plasma (4 % (w/v) 
sodium citrate) were added to each vial containing 35 mg of dried hydrogel.   The vial 
was then rotated for 18 hours on a Barnstead International Labquake.  After the 18 
hour cycle the coagulate complex was drained of plasma, and visually scored for 
fibrin formation on a scale of 0 (no fibrin formation) to 10 (substantial fibrin 
formation).   
 
2.2.7 Dynamic Mechanical Analysis 
 
All hydrogel compositions tested in the Dynamic FVII Activation Experiment 
above were tested with a TA Instruments (New Castle, DE) Q800 dynamic 
mechanical analyzer under submersion compression mode.  Hydrogel disks were 
immersed in DI water (multi-frequency) or citrated (4 % (w/v) sodium citrate), 
human plasma (stress-strain) for at least 18 hours.   All samples were submerged in 




testing.  Moduli were determined by fitting linear curves in the selected regions of 
strain. 
 
2.2.8 Factor Deficient and Factor Inhibition Experiment   
 
The hydrogel composition of 1.5 M APM, 1.5 M acrylamide, and 0.3 M 
acrylamide (Composition C in above Dynamic FVII Activation Experiment) was 
tested with various factor deficient and factor inhibited plasmas.  After the 18 hour 
cycle the coagulate complex was drained of plasma, and visually scored for fibrin 
formation on a scale of 0 (no fibrin formation) to 10 (substantial fibrin formation).   
Factor deficient plasmas were prepared via the immunodepletion of citrated (4 % 
sodium citrated), normal human plasma (Haemtech Inc.).  Factor inhibited plasmas 
were prepared by adding the necessary amount of chemical inhibitor to normal, 
human plasma (4 % (w/v) sodium citrate) to obtain the appropriate concentration for 
factor inhibition.  CTI at a concentration of 7 µM was used to inhibit FXIIa
85
.  
GGACK at a concentration of 500 µM was used to inhibit FXa and PPACK at a 
concentration of 200 µM was used to inhibit FIIa
86
.  Although PPACK and GGACK 
have been shown to have secondary targets, their primary targets are FIIa and FXa 
respectively.  1.11 mL of factor deficient or factor inhibited human plasma were 
added to a vial containing 35 mg of dried hydrogel, which was then rotated for 18 






2.2.9 TFPI Activity Experiment 
 
The same protocol used for the Dynamic FVII Activation Experiment including 
the same control compositions was used for the TFPI Activity Experiment.  The 
aliquoted samples were then analyzed to determine TFPI activity using an American 
Diagnostica ACTICHROME TFPI Activity Assay.  The ACTICHROME TFPI Activity 
Assay is a three stage chromogenic assay which measures active TFPI in plasma 
using a highly specific FXa substrate. 
 
2.2.10 Artificial Plasma Experiment   
 
Composition C (1.5 M APM, 1.5 M acrylamide, 0.3 M BIS) along with the HEM 
CTRL (1.5 M HEM, 1.5 acrylamide, 0.3 M BIS), used in previous experiments were 
tested in this experiment.  The artificial plasma was based on a platelet-suspension 
buffer used by Motlagh et. al.
87
, composed of 137 mM NaCl, 2.7 mM KCl, 0.4 mM 





, 100 µg/mL FII
90
, 7 µg/mL FV
91
, 5 µg/mL FIX
92
, 2.6 mg/mL FI
89
, 
and 30 µg/mL FXIII
93
.  1 mL of this artificial plasma was added to each vial 
containing 35 mg of dried hydrogel, which was then rotated for 18 hours.  The 








2.3 Results  
 
We utilized a primary amine containing functional monomer, within various 
polymer hydrogel compositions, to help isolate the specific effects that positive 
electrostatic charge and mechanical microstructure have on FVII activation in citrated 
plasma.  Histological and microscopic characterization techniques were used to 
investigate the formed coagulate complex.  A dynamic FVII activation experiment 
confirmed the ability of multicomponent charged hydrogel compositions to induce 
FVII activation and offered insight into the dependence on electrostatic charge and 
mechanical structure.  Dynamic mechanical analysis (DMA) was used to establish a 
correlation between polymer microstructure, and ability of the polymer hydrogel to 
induce FVII activation.  Experiments utilizing artificial plasma, coagulation factor 
depleted and coagulation factor inhibited plasmas, and an assay capable of 
determining TFPI activity were conducted in order to elucidate the biological 
mechanism by which the charged material was inducing fibrin formation.   
Due to the lack of free calcium in citrated plasma the kinetics of fibrin formation 
were considerably delayed, and because of this a longer incubation time (18 hours) 
was chosen for all experiments.  This time period allowed for the qualitative 
assessment of the ability of the material to activate the cascade, based on the amount 
of fibrin formed.  It should be noted that no fibrinolysis was observed in any of the 
experiments and that the formed clots were stable for several days after the 18 hour 
incubation period.  An example of the clot formed by the hydrogel in the 18 hour 





Figure 2.1:  Typical coagulate complex (fibrin-hydrogel complex) formed after rotating a specific 
hydrogel composition (1.5 M APM, 1.5 M acrylamide, 0.3 M BIS) in human plasma (4 % (w/v) sodium 
citrate) for 18 hours.  300 mg of dried hydrogel were placed in 9 mL of plasma. 
 
 
2.3.1 Characterization  
 
Various histological and microscopic techniques were used to investigate the 
microstructure of the clot formed in the presence of the charged hydrogel (Figure 
2.1).  Initial IHC staining, using a primary fibrinogen antibody, was completed on the 
complex to confirm the presence of fibrin (Figure 2.2A).  The fluorescence within the 
image clearly indicates the presence of fibrin within the complex, and suggests that 
the polymer is indeed activating the coagulation cascade.  H&E staining was 
completed to confirm the acellular fibrous nature of the clot and also to investigate 
the physical interaction and geometric configuration of the polymer relative to the 
fibrin.   The H&E stained micrograph, Figure 2.2B, clearly shows the presence of two 
distinct materials.  The polymer hydrogel appears as the smooth, lighter colored 




located on the left side of the micrograph.  The darker, acellular, fibrous appearance 
of this material is consistent with fibrin staining.     
 
Figure 2.2: (A) IHC stained micrograph image of coagulate complex.  (B)  H&E stained micrograph 
image of coagulate complex.  Polymer hydrogel appears as lighter, smoother material on right side of 
the micrograph while fibrin appears as the darker, rougher material on the left side of them micrograph. 
(C) ESEM surface image of the coagulate complex.   
 
ESEM was completed in order to further investigate the characteristics of the 
complex.  The ESEM image of the surface shows the presence of a continuous fibrin 
layer coating the exterior of the complex (Figure 2.2C).    Cross-sectional images 
showed little to no fibrin presence within the interior of the complex suggesting initial 
generation of fibrin is occurring at hydrogel particle surface, eventually leading to the 
aggregation and envelopment of the particles resulting in a fibrin-covered composite. 
 
2.3.2 Dynamic FVII Activation Experiment   
 
Initial experiments in citrated plasma, depleted calcium environment, proved the 
ability of a positively charged material to induce the activation of the coagulation 
cascade resulting in the formation of a fibrin-based clot.  A dynamic FVII activation 
experiment was completed in order to confirm the ability of such charged polymer 




necessary for this activation.  As Figure 2.3 shows, all compositions capable of 
inducing fibrin formation (compositions B, C, E) showed elevated levels of FVIIa 
compared to the controls (Figure 2.3, bar graph).  All compositions incapable of 
inducing fibrin formation (compositions A, D, F) showed FVIIa levels similar to the 
controls, consistent with normal physiologic concentrations (~ 5 ng/mL).  The 
elevated levels of FVIIa also closely correlated with the amount of fibrin formation 
generated by each respective composition (Figure 2.3, line graph).   Composition C 
induces substantial activation of FVII resulting in FVIIa concentrations 8 times the 
resting levels (5 ng/mL) after 30 minutes and almost 15 times the resting 
concentration after 180 minutes.   
 
 
Figure 2.3:  Factor VIIa concentration was measured in citrated human plasma containing various 
hydrogel compositions at 30, 90, and 180 minutes (left axis: bar graph).  The amount of fibrin formation 
was also rated for each composition at each time point (right axis: line graph).  Data is representative of 
an average and corresponding standard deviation (error bar) of three (n = 3) separate sample trials. 
Asterisk (*) indicates duplicate sample point. 
 
The data also provides insight into the critical parameters of this activation 
suggesting that both electrostatic positive charge, e.g. primary amine functionality on 




the activation of FVII.  Composition A, which contains a high amount of APM 
concentration yet low amount of cross-linking monomer, BIS, is unable to induce 
FVII activation.  Similarly, composition F which is highly cross-linked yet contains a 
minimal amount of positive electrostatic functionality, APM monomer, is also unable 
to induce FVII activation.  Subsequent investigation was completed in order to 
develop a better understanding of the critical electrostatic and mechanical parameters 
necessary for FVII activation and subsequent fibrin formation.  
 
2.3.3 Surface Area Dependence  
 
Previous experiments confirmed the ability of a positively charged polymeric 
hydrogel to induce the activation of FVII in citrated, platelet poor plasma.  Further 
experimentation was conducted in order to determine if FVIIa generation could be 
correlated to surface area. The composition which was capable of inducing the 
optimum amount of FVIIa as shown in the previous Dynamic FVII Activation 
Experiment, composition C (1.5 M APM, 1.5 M acrylamide, 0.3 M APM), was 
ground into 4 different particle sizes ranging from 53-425 μm to determine if there 
was a correlation between FVII generation and surface area.  A hydrogel composed of 
HEM (1.5 M HEM, 1.5 M acrylamide, 0.3 M BIS), used in the Dynamic FVII 
Activation Experiment, was used as a negative control.  As Figure 2.4 below shows, 
there appears to be no correlation between the presented surface area of the hydrogel 
and FVIIa generation.  The particles within the range of 53-150 μm have considerably 
more surface area than the particles in the range of 355-425 μm yet the difference in 




parameter, at least between 50 and 450 μm.  The data suggests that the surface area 
exposed by 450 μm particles is already sufficient to induce the activation of FVII, and 
increasing this surface area has no effect on enhancing the ability of the material to 
induce the phenomenon.   
 
Figure 2.4: Factor VIIa concentration was measured in human plasma containing various particle sizes 
of a hydrogel capable of inducing FVII (composition C from above Dynamic FVII Activation Experiment) 
or a negative control (HEM Control) at 30, 90, and 180 minutes.  Data is representative of an average 
and corresponding standard deviation (error bar) of three (n = 3) separate sample trials.  Asterisk (*) 
indicates duplicate sample point.  
 
2.3.4 Optimization  
 
After a FVII activation experiment confirmed the ability of the polymer to induce 
the activation of FVII resulting in the subsequent formation of fibrin, an optimization 
study was conducted to investigate the effects that certain material and chemical 
properties had on the ability of the hydrogel to induce fibrin formation (FVII 
activation).  Various compositions of polymer hydrogels were synthesized and tested 




concentration (APM + acrylamide + BIS), positive electrostatic charge (APM), and 
cross-linker ratio (acrylamide:APM:BIS) had on this phenomenon.  
The data from this optimization experiment is arranged in a two dimensional grid, 
where each box depicts a specific monomer composition (Figure 2.5).  The ability of 
each composition to induce fibrin formation was visually scored according to fibrin 
presence, from 0 (no fibrin formation) to 10 (substantial fibrin formation).  Each 
composition box is color coded according to the rating scale located on the bottom of 
the figure.  Images representative of fibrin formation ratings 0, 2, 4, 6, 8, and 10 are 
shown immediately below the scale for visual reference. 
 
Figure 2.5:  Experiment aimed to investigate the effect that various compositional factors including total 
monomer concentration (acrylamide + APM + BIS), positive electrostatic charge (APM), and cross-linker 
ratio (acrylamide:APM:BIS) had on fibrin formation (FVII activation).  Acrylamide concentration is 
located on the horizontal axis while APM concentration is on the vertical axis.  BIS concentration is also 
indicated on the horizontal axis and is kept constant for each respective acrylamide concentration.  The 
amount of fibrin formation induced by each composition was visually scored from 0 (no fibrin formation) 
to 10 (substantial fibrin formation).  Images of representative fibrin formation (clot) ratings 0, 2, 4, 6, 8, 
and 10 are displayed underneath the rating scale for visual reference. All samples were run in triplicate 





No hydrogels composed purely of acrylamide and BIS were able to induce fibrin 
formation, indicating that the charge of the APM monomer, i.e. positive electrostatic 
charge on the primary amine, is vital to the process.  It is also apparent from the data 
that the ability of the material to induce fibrin formation is highly dependent on the 
creation of a tightly cross-linked network.  The 1.5 M APM concentration line 
(horizontal left to right) clearly indicates this dependence.  At low acrylamide and 
BIS concentrations, the synthesized 3-component hydrogel is unable to induce fibrin 
formation, but as both of these parameters are increased, the ability of the hydrogel to 
induce fibrin increases considerably.  This structural dependence is also evident, 
considering the composition capable of eliciting the optimum amount of fibrin shown 
in previous experiments (Composition C from Dynamic FVII Activation 
Experiment).  This hydrogel consists of 1.5 M acrylamide, 1.5 M APM, and 0.3 M 
BIS.  This optimum composition is able to induce a substantial amount fibrin, yet 
when the concentration of BIS is reduced from 0.3 to 0.15 M, the ability of the 
hydrogel to induce fibrin formation is completely lost.  Increasing acrylamide and 
BIS concentration results in the creation of a more tightly cross-linked network, this 
in turn, leads to an increase in mechanical stiffness of the material.  Results from this 
experiment suggest the appropriate balance of positive electrostatic charge and 
mechanical stiffness is essential to optimizing the polymer’s ability to induce fibrin 






2.3.5 Dynamic Mechanical Analysis 
 
The optimization experiment indicated that the ability of a polymeric hydrogel to 
induce FVII activation and subsequent fibrin formation in citrated plasma was 
dependent on both an electrostatic and mechanical component.  Although several 
research groups have investigated the role of positive electrostatic charge in FVII 
activation in various medium, no groups, to the best of the authors’ knowledge, have 
investigated the structural dependence of this activation in citrated (calcium depleted) 
plasma.  Dynamic mechanical analysis (DMA) was used to investigate the 
relationship between specific mechanical properties and the ability to activate FVII 
and induce fibrin formation.  DMA measures the mechanical properties of a material 
as a function of time, temperature, and frequency.  There is a direct correlation of 
measured mechanical properties to microstructure.  Multi-frequency experiments 
were conducted in order to investigate the heterogeneity of the material, while stress-
strain experiments were conducted to determine stiffness and bulk mechanical 
properties. 
The storage modulus is related to the stiffness of the material, while the loss 
modulus to damping and energy dissipation.  Low frequency transitions are attributed 
to liquid-like properties of the material, where flow dominates.  High frequency 
transitions are characteristic of more solid-like behavior, where elastic properties are 
prevalent.    The multiple peaks in each composition’s loss modulus clearly indicate 
that each polymer hydrogel is not homogeneous, but consists of multiple regions of 
mechanical equivalence.  The compositions containing high to medium APM content 




indicating that these hydrogels contain a softer, more liquid-like region (Figure 2.6).  
The transitions of the low APM, high acrylamide composition (composition F) occur 
only in the higher frequency ranges, consistent with a stiffer material.  
 
Figure 2.6:  Graph of loss modulus vs. frequency of three compositions used in the Dynamic FVII 
Activation Experiment ranging from high APM, low acrylamide and BIS content (composition A) to low 
APM, high acrylamide and BIS content (composition F).  Spectra for sample compositions C and F are 
shifted vertically to avoid overlapping of data.  Spectra are representative of data obtained from several 
samples (n = 3 – 5). 
 
Stress-strain experiments were conducted to further corroborate a direct 
relationship between the mechanical stiffness of the hydrogel and its ability to induce 
FVII activation, and subsequent fibrin formation.  As Figure 2.7 below shows, each 
composition exhibits distinctly different stress-strain behavior.  Moduli for both the 
linear elastic region, between 0 % and 1 % strain, and the strain hardening region, 
between 4 % and 5 %, were determined to establish a quantitative assessment of 
material stiffness (Table 2.1).  The moduli were calculated by fitting a linear 
regression to the data for each respective region and obtaining the slope.  Of all the 
experimental samples, disregarding control samples, the optimum composition 




hardening modulus.  This enhanced stiffness of the optimum composition, most likely 
due to an ideal combination between physical and chemical cross-linking, along with 
the integration of positive charge results in a material capable of sustained activation 
of FVII and the corresponding coagulation cascade.  
 
Figure 2.7:  Stress-strain graph of all sample compositions used in the Dynamic FVII Activation 









Table 2.1:  Both the linear elastic modulus (calculated between 0 % - 1 % strain) and the strain 
hardening modulus (calculated between 4 % - 5 % strain) were calculated for all sample compositions 
used in the Dynamic FVII Activation Experiment. The moduli were calculated by fitting a linear 
regression to the data for each respective region and obtaining the slope.  3 to 5 samples were used for 
each calculation (n = 3 – 5).   
 
The relationship between material stiffness of the hydrogel and its ability to 
induce FVII activation and fibrin formation in citrated plasma is clearly demonstrated 
in the differences in elastic moduli between samples C and D.  Both samples contain 
the identical amount of positive charge (APM) and differ only in cross-link density 
(BIS) yet, composition C is capable of strongly inducing FVII activation and fibrin 
formation, while composition D is incapable of inducing FVII activation and fibrin 
formation.  This mechanical dependence is further corroborated by the stress-strain 
data from compositions A and C.  Although, the amount of positive charge in 
composition A is almost twice that of composition C, composition A is incapable of 
inducing FVII activation and fibrin formation due to decreased material stiffness.  
This effect could also be attributed to a difference in charge density of the exposed 




will be conducted in order to investigate the water uptake of specific polymer 
hydrogel compositions to determine if there is a correlation with FVII activation and 
fibrin formation.  In any case, the results clearly demonstrate that there is a structural 
dependence on the ability of the polymer to induce FVII activation and fibrin 
formation. Furthermore, the results indicate that both electrostatic charge and 
adequate mechanical stiffness are necessary for the process and the appropriate 
balance of these two parameters leads to the creation of a polymer with optimized 
ability for FVII activation and fibrin formation.  
 
2.3.6 Biological Mechanism  
 
Previous experimentation utilizing a FVIIa specific ELISA confirmed the ability 
of a polymeric hydrogel to induce the activation of FVII in citrated, platelet poor 
plasma.  Furthermore, previous optimization experiments and dynamic mechanical 
analysis was used to help establish both an electrostatic and structural dependence for 
FVIIa activation within citrated plasma.  Although these experiments helped to 
elucidate the critical material properties necessary for FVII activation they offered 
little insight into the biological mechanism by which fibrin formation was occurring.  
Successive experimentation was aimed at investigating the biological mechanism of 
tissue factor pathway activation and subsequent fibrin formation including the vital 
biological components and cofactors involved.  Factor deficient and factor inhibited 
(chemical inhibition) plasmas were used to determine the biological factors which 
were vital to the mechanism.  A specifically designed chromogenic assay was utilized 




artificial plasma was conducted in order to determine whether platelets, calcium, and 
TF were significant to the mechanism by which the polymer was inducing fibrin 
formation.   
Experimentation utilizing various factor deficient and factor inhibited plasmas 
was completed in order to determine the coagulation factors which were vital to the 
mechanism by which the hydrogel was inducing fibrin formation (Figure 2.8).   
 
Figure 2.8:  Optimum hydrogel composition (Composition C from above Dynamic FVII Activation 
Experiment) tested in various factor deficient and factor inhibited plasmas for 18 hours.  After the 18 
hour cycle the coagulate complex was drained of plasma, and visually scored for fibrin formation on a 
scale of 0 (no fibrin formation) to 10 (substantial fibrin formation).  All samples were run in triplicate (n = 
3).    
 
As predicted by earlier experimentation, removal of FVII from plasma severely 
inhibited the ability of the hydrogel to induce fibrin formation relative to the normal, 
plasma control, indicating that FVII is indeed vital to the process.  The small amount 
of fibrin formed is believed to be induced by the trace amounts of FVII not 
sufficiently removed in the purification process.  Removal of FX also severely 
inhibited clotting.  When FXa was inhibited using L-glutamyl-L-glycyl-L-arginine 




observed.  These results, along with known mechanics of the coagulation cascade, 
suggest that FX is vital to the mechanism, and that the small amount of fibrin formed 
in the FX deficient plasma was induced by trace amounts FX not properly removed in 
the purification (immunodepletion) process.  The removal of FII, or the chemical 
inhibition of FIIa using D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
(PPACK), led to complete inhibition of fibrin formation.  Also, the data seems to 
agree with suggested theory of the ability of positively charged surfaces to initiate the 




Removal of FV, a cofactor of FII, had no significant effect on fibrin formation 
suggesting that this cofactor is not vital to fibrin formation in the presence of a 
positively charged surface at depleted calcium levels
80,82
.  As predicted removal of FI, 
fibrin, resulted in complete inhibition of fibrin formation.  Results from this 
experimentation suggest that FVII, FX, FII, and FI are all vital to the process, 
indicating that the biological mechanism of action of the polymer is via the activation 
of the tissue factor pathway, which leads to the subsequent activation of the common 
pathway, eventually resulting in fibrin formation. 
Removal of FXII or chemical inhibition of FXIIa using corn trypsin inhibitor 
(CTI) showed little to no effect on fibrin formation when compared to normal human 
plasma.  Similarly, removal of FXI had negligible effect on the ability of the polymer 
to induce fibrin formation, indicating that these factors, or rather the contact 




Removing FIX from plasma did reduce fibrin formation but did not completely 
inhibit the process.  While removal of FIX had a modest inhibitory effect on fibrin 
formation, removal of its primary cofactor FVIII had almost no effect on fibrin 
formation.  While the data corroborates previous findings that positively charged 
surfaces are capable of enhancing the activation of FX by activated FIX in calcium 
depleted plasma, it further suggests that this mechanism is secondary to direct 
activation of FVII. 
After investigating the vital coagulation factors and outlining a general 
mechanism of fibrin formation in the presence of charged hydrogels, experiments 
were conducted to understand roles that various cofactors and inhibitors had on this 
mechanism.  Under normal physiologic circumstances, the FVIIa-TF-FX complex is 
rapidly bound and inhibited by TFPI.  A strong electrostatic interaction could 
theoretically prevent TFPI from appropriately binding to its substrates, thereby 
reducing its inhibitory ability, although in the absence of TF, no TFPI activity is 
expected.  To explore the role of TFPI in this process, a specifically designed TFPI 
activity assay (American Diagnostica ACTICHROME TFPI Activity Assay) was used.  
There appeared to be no outlying trend of TFPI activity for any of the experimental 
samples compared to the control samples (Figure 2.9), suggesting that the hydrogel is 
not interfering with the inhibitory activity of TFPI.  The compositions which are able 
to induce fibrin formation (compositions B, C, E) showed no visible or statistical 
variation in TFPI activity compared to the rest of the experimental samples or any 
control samples.  These results strongly indicate that the polymer is not interfering 






Figure 2.9:  TFPI Activity was measured in human plasma containing various hydrogel compositions at 
30, 90, and 180 minutes (left axis: bar graph).  The amount of fibrin formation was also rated for each 
composition at each time point (right axis: line graph).  Data is representative of an average and 
corresponding standard deviation (error bar) of three (n = 3) separate sample trials.  Asterisk (*) 
indicates duplicate sample point. 
 
The complete and successful activation of the tissue factor pathway requires the 
coordination and interaction of a multitude of cofactors including calcium, platelets, 
and TF.  Previous work by has shown the ability of positively charged polymers to 
induce the autoactivation of FVII and to assist in the activation of FX by FVIIa and 
FIXa in medium with depleted calcium levels.  Although platelets and TF enhance 
this process it has been shown that these cofactors are not necessary for these 
activation steps.  To further investigate the role of these cofactors in the biological 
mechanism, an experiment was conducted using “artificial plasma” consisting of only 
FVII, FIX, FX, FV, FII, FXIII, and FI (fibrin) and explicitly lacking calcium, TF, and 





Figure 2.10:  (A) Image of hydrogel capable of inducing optimum FVII activation, Composition C used 
in previous experimentation, (orange cap), along with a HEM control hydrogel (blue cap) and a blank 
control (red cap) after 30 minute rotation in artificial plasma explicitly lacking calcium, tissue factor (TF), 
and platelets.  Arrow shows fibrin clot formation. Artificial plasma consisted of 137 nM NaCl, 2.7 mM 
KCl, 0.4 mM sodium phosphate monobasic, 5.5 mM dextrose, 10 mM HEPES, 0.5 µg/mL FVII, 10 
µg/mL FX, 100 µg/mL FII
31
, 7 µg/mL FV
32
, 5 µg/mL FIX, 2.6 mg/mL FI, and 30 µg/mL FXIII. (B) IHC 
stained image of clot formation observed with composition C. 
 
As Figure 2.10 shows the composition C was able to induce fibrin formation in 
the artificial plasma within minutes, and by 30 minutes a substantial fibrin-based 
aggregate formed which was confirmed using IHC.  Although the artificial plasma 
was also void of the inhibitory mechanisms naturally present in plasma, the results do 
indicate that the polymer is capable of inducing fibrin formation through the rapid 




Charged polymer hydrogels were used to help elucidate a better understanding of 
the critical material properties necessary for the activation of FVII and subsequent 
fibrin formation in citrated, platelet-poor plasma.  Characterization experiments 
confirmed the generation of fibrin and also provided insight into the microstructure of 





polymer hydrogels to induce FVII activation.  The results of the Dynamic FVII 
Activation Experiment suggested that cross-link density or mechanical rigidity, in 
addition to positive electrostatic charge, was crucial to FVII activation.  Dynamic 
mechanical analysis was conducted in order to establish a structural correlation 
between the mechanics of the polymer microstructure and FVII activation.  
Experiments utilizing factor deficient and factor inhibited plasmas showed that FVII, 
FX, FII, and FI are all vital to the process, outlining the general mechanism of 
coagulation activation and fibrin formation.  A TFPI activity assay indicated that the 
inhibitor had little effect on the ability of the charged polymer to induce FVII 
activation and fibrin formation, most likely due to the lack of TF in the media. 
Several of the protein factors which play a vital role in the ability of the material 
to induce fibrin formation, i.e. FVII, FX, and FII, are vitamin-K dependent serine 
proteases.  Previous research has found that these proteins may be separated from 
various other coagulation proteins through the presentation of a highly positively 
charged surface and furthermore that such positively charged surfaces are capable of 
enhancing the activation of these coagulation factors in calcium depleted media
76-82,94
.  
It is believed that the coordination of these factors occurs through the electrostatic 
binding between the positively charged surface and the Gla domains of the enzymes.  
In calcium depleted medium the majority of the Gla domains of these factors lack 
calcium which results in the presentation of a highly negatively charged capable of 
interacting with a positively charged surface
76-82,94
.  Although the role of electrostatic 
charge in this phenomenon is well known we have shown that there is also a critical 




correlation between the rigidity of the material, i.e. elastic and strain hardening 
modulus, and the ability of the material to induce FVII activation resulting in fibrin 
formation.  Previous reports have suggested that the molecular weight and/or the 
concentration of polymer used are the key parameters yet our results indicate that it is 
the structural rigidity of the charged surface which determines the ability of the 
polymer to induce FVII activation. 
A better understanding of the interactions that occur between synthetic surfaces 
and biological substrates is key to the development of future biomaterial technology.  
It is imperative we understand the critical parameters which are able to affect in vivo 
biological processes, specifically the coagulation cascade, in order to develop more 











  The body’s initial response to injury involves the selective deposition and 
adherence of platelets to the subentholelium layer of the disruption site via collagen. 
Interaction with collagen and other molecules contained within the subendothelium, 
e.g. ADP, also activates the platelets inducing the formation of several pseudopodia 
tentacles.  Activation also induces platelets to release several molecules including 
fibrinogen, ADP, vWF, platelet factor 4, and thrombospondin, which assist in 
subsequent platelet aggregation and activation.  Initial activation, aggregation, and 
deposition of platelets to the wound site is crucial to the formation of a platelet plug 
to control initial blood loss.  This platelet plug is eventually stabilized by fibrin to 
produce a robust hemostatic clot. 
Previous in vitro experimentation focused on investigating the specific material 
factors which affect the activation of the coagulation cascade in citrated plasma, 
specifically the activation of FVII.  Subsequent research utilizing clinical diagnostic 
and live animal experiments was conducted in order to investigate the critical material 
parameters key to promoting the formation of an effective platelet plug in a clinically 
relevant model.  The end goal of this research was the translation of in vitro and in 





3.2 Materials and Methods 
3.2.1 Materials 
 
Acrylamide, N,N’-methylenebisacrylamide (BIS),  N,N,N’,N’-
tetramethylethylenediamine (TEMED), and ammonium persulfate (APS) were 
purchased from Sigma-Aldrich (Milwaukee, WI).  N-(3-aminopropyl)methacrylamide 
hydrochloride (APM) was purchased from Polysciences (Warrington, PA).  N-(2-
hydroxyethyl)methacrylamide (HEM) was purchased from Monomer-Polymer 
(Trevose, PA).  Deionized water (DI water) was obtained using a Millipore Super-Q 
water system (Billerica, MA).  Plastic capped glass vials were purchased from VWR 
Scientific (West Chester, PA).   
 
3.2.2 Hydrogel Synthesis 
 
A specific amount of either acrylamide, N,N’-methylenebisacrylamide (BIS), N-
(2-hydroxyethyl)methacrylamide (HEM), or N-(3-aminopropyl)methacrylamide 
hydrochloride (APM)  was dissolved in DI water and mixed thoroughly until all 
components were completely solvated.  The solution was then titrated to a pH 
between 6.8 and 7.2 using sodium hydroxide (NaOH) and/or hydrochloric acid (HCl).  
After pH adjustment, the monomer solution was initiated by adding 20 µL/mL of a 
7.5 % (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED) solution, followed by 
adding 20 µL/mL of a 15 % (w/v) solution of ammonium persulfate (APS), for 
polymerization.  For the fresh sheep blood experiments the hydrogels were crushed 
after formation and portioned accordingly for testing.  For all animal clinical trials the 




dried in a vacuum oven overnight, crushed with a mortar and pestle, and sieved to 
obtain particles between 75 and 250 µm.  
 
3.2.3 Sheep Blood Experiments 
 
Fresh blood was taken intravenously from an adult Dorsett hybrid sheep (~ 65 
kg).  After drawing approximately 1 mL of fresh blood was added to a glass or 
polypropylene vial, containing 250 mg of hydrogel sample.  The ability of the 
hydrogel to form a clot was visually observed.  During the course of the study, all 
animals received humane care in accordance with the Guide for Care and Use of 
Laboratory Animals (National Institutes of Health publication 86-23, revised 1996). 
 
3.2.4 In Vivo Animal Experiments 
 
All surgeries were completed on an adult Dorsett hybrid sheep (~ 65 kg).  
Anesthesia was induced with thiopental sodium (10 mg/kg) and maintained by 
mechanical ventilation with 1 % - 2 % isoflurane mixed with oxygen.  A Draeger 
anesthesia monitor (North American Draeger, Telford, Pa) was used during the 
surgery.  Immediately after the surgery the respective tissue (lung or liver) was 
excised, and analyzed using various staining techniques including hematoxylin & 
eosin (H&E) and Carstairs’ method.    The surgical protocol and animal care were 
approved by the Institutional Animal Care and Use Committee of the University of 






3.2.4.1 Lung  
 
An incision, approximately 5 cm in length and 1 cm in depth, was made with a 
surgical scalpel on the anterior or ventral side of the sheep’s lung.  The hydrogel 
bandage was then applied to the wound site, with slight pressure, for approximately 2 
minutes.  The bandage consisted of simple gauze with 1500 mg of dried hydrogel 
(2.73 M APM, .27 M acrylamide, .054 M BIS) on the surface.  5 mL of DI water 
were sprayed on the bandage to facilitate the adherence of the hydrogel to the gauze.   
 
 
3.2.4.2 Liver  
 
An incision, approximately 5 cm in length and 1 cm in depth, was made with a 
surgical scalpel on the anterior or ventral side of the sheep’s liver.  Approximately 
750 mg of dried hydrogel were poured into the laceration, which was then 
compressed with gauze for approximately 4 – 5 minutes.   
 
 
3.2.4.3 Histological Staining  
 
5 µm sections of each respective incision site (lung or liver) were obtained and set 
in paraffin.  The sections were then deparaffinized with xylene and rehydrated with a 
series of graded alcohol solutions.  Hematoxlyin and eosin (H&E) along with the 








Initial in vitro experiments focused on understanding the material parameters 
which effect coagulation cascade activation and fibrin formation in citrated, platelet 
poor plasma.  Subsequent research utilizing fresh blood and in vivo animal trials was 
conducted to understand the critical material components key to the formation of an 
effective hemostatic seal in vivo.  The specific goal of the research was to determine 
the viability of a charged polymer hydrogel to effectively control blood loss in a 
clinically relevant model. 
 
3.3.1 Sheep Blood Experiments 
 
Experimentation utilizing unadulterated (lacking any type of anticoagulation) 
sheep blood drawn directly from the animal was conducted to identify and isolate the 
vital material properties associated with rapid and effective clot formation.  Initial 
experiments in the presence of a FXII activation surface (glass surface) showed the 
ability of specific formulations to induce rapid platelet aggregation resulting in a 
robust hemostatic clot within 5 minutes.  Polymeric hydrogels systemically ranging in 
both positive electrostatic charge and mechanical stiffness were synthesized and 
tested with sheep blood in the presence of a coagulation cascade activator (glass 
surface).  Within the presence of a coagulation activator hydrogel compositions 
consisting of higher amounts of electrostatic charge (increased ratio of 
APM:acryamide + BIS) and lower cross-link density (decreased ratio of 




formation. A specific polymer formulation consisting of 2.73 M APM, 0.27 M 
acrylamide, and 0.054 M BIS was capable of inducing the formation of a robust clot 
within 3 minutes compared to a control which took over 10 minutes.  Subsequent 
qualitative inspection of the clots showed that the clot formed by the hydrogel was 
considerably more robust than the control (Figure 3.1). 
 
Figure 3.1: Clot Formation in Sheep Blood.  Clot formations induced by the hydrogel compared to a 
blank control.  Approximately 1 mL of sheep blood, drawn directly from the animal, was added to a 
glass vial containing 250 mg of polymer hydrogel (2.73 M APM, 0.27 M acrylamide, and 0.054 M BIS) 
along with a blank glass vial.  Clot formation was induced by the hydrogel in approximately 3 minutes 
compared to clot formation observed in the blank control which took over 10 minutes.     
 
Experiments were also conducted in polypropylene vials to investigate the ability 
of specific hydrogel formulations to induce clot formation without the addition of a 
coagulation cascade activator (glass surface).  Without the addition of a coagulation 
activator, polymeric hydrogels consisting of higher electrostatic charge and lower 
cross-link density, lower mechanical stiffness, were incapable of inducing fibrin 
formation.  Although these hydrogel formulations dramatically increased the viscosity 
of the blood, most likely due to the absorption of water, platelets, and erythrocytes, 
they delayed the onset of fibrin formation compared to a blank control sample.  
Contrary to hydrogels composed of higher amounts of electrostatic positive charge 




and lower cross-link density, formulations of lower amounts of positive charge and 
higher cross-link density expedited the onset of fibrin formation.  Furthermore, 
experimentation showed that a hydrogel composition which completely inhibited 
fibrin formation could be engineered to promote the onset of fibrin formation by 
increasing cross-link density, regardless of positive electrostatic charge.     
The results of this blood experimentation clearly indicated the importance of both 
positive electrostatic charge and cross-link density in both primary and secondary 
hemostasis.  Increased positive electrostatic charge and decreased cross-link density 
seemed to enhance the ability of the polymer to aggregate platelets and erythrocytes 
yet inhibited coagulation cascade activation.  Hydrogels composed of lower amounts 
of positive electrostatic charge and higher cross-link density expedited fibrin 
formation yet were ineffective at forming a robust platelet plug do to, what is 
believed to be, the inability to absorb platelets and erythrocytes.   Subsequent animal 
experimentation was conducted in order to further investigate the critical material 
properties involved with primary and secondary hemostasis in vivo.  
 
3.3.2 In Vivo Animal Experiments 
 
Previous sheep blood experimentation had shown that hydrogel compositions 
consisting of higher positive electrostatic charge and lower cross-link density were 
better able to induce the aggregation of platelets and erythrocytes to generate an 
effective hemostatic plug, especially in the presence of an activator.  In vivo animal 
experimentation was conducted in order to determine whether the obtained in vitro 




experimentation was to investigate the ability of a charged polymer hydrogel to 
control hemorrhaging in a clinically relevant model.  The global aim of the research 
sought to identity the key material properties which were vital to enhancing both 
primary and secondary hemostasis to induce the formation of an effective hemostatic 
clot.   
All experimentation was conducted on adult hybrid Dorsett sheep.  Sheep were 
chosen as a model due to the fact that their arteries are similar in size to that of 
humans, and their coagulation and fibrinolytic systems are closer to those of humans 




3.3.2.1 Lung  
 
Immediately after the incision was made a gauze pad containing the hydrogel was 
placed directly on the wound site, to which slight pressure was applied for 1 minute 
(Figure 3.2A-B).  After 2 minutes the gauze pad containing the hydrogel was 
removed and the wound site was washed with saline solution and visually inspected.  
As Figure 3.2C shows the hydrogel was able to completely seal the incision 
effectively stopping blood loss in approximately 2 minutes.  Immediately after the 












Hematoxylin & eosin staining was conducted on the incision site to investigate 
the microstructure of the clot (Figure 3.3).  The stained micrographs show the 
presence of a fibrin matrix embedded with various types of cells including 
erythrocytes, leukocytes, and platelets consistent with the microstructure of a typical 





Gauze Pad (with Hydrogel) 
Sealed Incision  
(Bleeding Stopped) 
Figure 3.2:  Image of lung incision site before hydrogel is applied (A), during the application of the 




ability of the hydrogel to induce the formation of an effective hemostatic platelet plug 
to control blood loss.    
     
 
 
3.3.2.2 Liver  
 
After confirming the ability of the hydrogel to induce rapid and effective 
hemostasis on the lung, experiments were conducted on the liver to determine if the 
hydrogel could control more severe hemorrhaging.  The liver is considerably more 
vascularized than the lung which makes hemorrhaging from the liver incredibly 
difficult to control.  Simple compression is typically unable to stop blood loss from 
the liver and the delicacy of the tissue makes it very hard to suture with conventional 
stitches.  A material capable of inducing rapid and effective hemostasis on the liver 
would be a great benefit to the field. 
The protocol for the liver incisions was kept consistent with the protocol used for 
previous lung experimentation.  Immediately after the incision was made the hydrogel 
was applied to the wound site where slight pressure was applied with a gauze pad for 
approximately 5 minutes.  After 5 minutes the pad was removed and the wound site 
was washed with saline solution and visually inspected.   




Figure 3.3:  Optical micrographs of H&E stained sections of the lung incision site.  Magnifications of 5x 




Several different hydrogel compositions were tested and, as in the case with the 
lung experiment, the composition consisting of 2.73 M APM, 0.27 M acrylamide, and 
0.3 M BIS was able to induce hemostasis most effectively.  The polymer was able to 
induce complete hemostasis in approximately 5 minutes.  Figure 3.4B clearly shows 
that the hydrogel was able to induce a robust hemostatic seal, effectively stopping 
blood loss from the wound site. 
           
 
 
Histological staining of the wound site was completed immediately after the 
experiment in order to further investigate the microstructure of the hemostatic seal.  
H&E staining confirmed the formation of an effective hemostatic clot at the wound 
site (Figure 3.5).  Substantial fibrin formation can be seen within the incision site, 
bridging the wound from each tissue.  Much of the fibrin formation is emanating from 
the surfaces of the hydrogel particles suggesting that the particles provided an active 
surface for coagulation activation and subsequent fibrin generation.  Furthermore, 
several cell-like bodies, which are believed to be erythrocytes, platelets, and/or 
A B 
Figure 3.4:  (A) Image of the initial liver incision site, before hydrogel is applied.  (B) Image of same 





leukocytes, are embedded within the fibrin matrix forming what appears to be an 
effective hemostatic plug. 
      
 
Carstairs’ histological method was used to positively identify the critical 
components of the hemostatic seal (Figure 3.6).  Carstairs’ method is a common 
histological technique to distinguish platelets (grey), fibrin (orange-red), collagen 
(blue), platelets (grey), and erythrocytes (red-yellow).   
 
 
Figure 3.5:  H&E stained micrographs of the liver incision site. 
 
200 µm 200 µm  
Figure 3.6:  Carstairs’ Method stained micrographs of liver incision site.  Fibrin (red-orange), collagen 







Carstairs’ staining positively confirmed the generation of fibrin at the incision 
site.  The micrographs agree with H&E stained images of the incision site indicating 
that fibrin generation spawns from the hydrogel particles into the wound.  Platelets 
and erythrocytes (yellow and grey particles) can be observed both within the fibrin 
mesh along with deep inside the wound site.  Results from the histological staining 
clearly demonstrated the ability of the hydrogel to induce and enhance the formation 




Experimentation using sheep blood suggested positive electrostatic charge and 
cross-link density were key determinants of the ability of the material to induce or 
enhance clot formation.  Hydrogel formulations composed of higher amounts of 
positive electrostatic charge and lower cross-link density were able to effectively 
induce and enhance clot formation in the presence of a coagulation activator.  
Interestingly, without the addition of a coagulation cascade activator such hydrogels 
delayed and in some cases completely inhibited fibrin formation, which subsequently 
inhibited the formation of an effective clot.  Hydrogel compositions of higher cross-
link density enhanced the onset of fibrin formation yet were not nearly as effective at 
aggregating platelets and erythrocytes.   
Both platelets and erythrocytes have a net negative charge, therefore increasing 
the positive electrostatic charge of the hydrogel should increase its affinity for both 




cross-link density allows the hydrogel to swell more, take up more liquid volume 
which most likely aids in both obstructing blood flow and adhering more platelets, 
erythrocytes, and leukocytes to generate a more effective platelet plug.  On the other 
hand, it seems stiffness, i.e. cross-link density, is a key parameter in order to 
effectively enhance the activation of the coagulation cascade in fresh blood.  Without 
the presence of an activator, hydrogels of lower cross-link density, lower stiffness, 
delayed the onset of fibrin formation and in some cases completely inhibited the 
process.  Interestingly, regardless of electrostatic charge, the ability of a polymer 
hydrogel to enhance fibrin formation could be tuned by changing only the relative 
cross-link density ranging from complete inhibition (low cross-link density) to 
acceleration (high cross-link density) of the process.  Results indicate that the 
structure or stiffness of the hydrogel is crucial to providing an effective surface for 
coagulation cascade activation.  
 In vivo experimentation confirmed that hydrogels containing higher 
electrostatic charge with low cross-link density are more effective at controlling 
blood loss.  Highly cross-linked hydrogel formulations were ineffective at stopping 
blood loss, regardless of the amount of electrostatic charge.  A specific hydrogel 
formulation consisting of 2.73 M APM, 0.27 M acrylamide, and 0.3 M BIS was able 
to induce complete hemostasis of a lung incision in 2 minutes.  The same hydrogel 
was able to induce a hemostatic seal of a similar sized incision on the surface of the 
liver in approximately 5 minutes.   Histological staining of the wound site clearly 
indicated that the hydrogel was able to induce the formation of an effective 




Furthermore, the images indicated that fibrin formation generated from the hydrogel 
particles suggesting that coagulation cascade activation was occurring on or in close 
proximity to the hydrogel surface.   
Biological-based hemostatics including those based on fibrin and/or thrombin 
typically take approximately 3 - 5 minutes to induce complete hemostasis of an 
internal organ incision such as the liver.  The fact that the hydrogel tested was capable 
of inducing a robust seal in approximately 5 minutes attests to the viability of such a 
material to be used as a surgical hemostatic.  Such a polymer-based hemostatic would 
have tremendous advantages over its biological counterparts including a lengthened 
shelf life, ease of production, no risk of virus transmission or biologically induced 
allergic reaction, and most importantly low price.  Such a synthetic hydrogel could be 
produced at a fraction of the price of its biological counterparts making such a 
material a viable option for developing countries where 90 % of blood loss deaths 
occur.  Research into the understanding of how synthetic materials interact with the 
body’s clotting process is integral to developing a safe, inexpensive, and effective 
material capable of enhancing or assisting it.  This research is key to the development 
of the next generation of hemostatic materials which will save millions of people 




4 Chapter 4: Contributions and Future Work 
 
4.1  Contributions 
 
This work represents a thorough investigation into how both electrostatic charge 
and mechanical stiffness of a polymer hydrogel material affect FVII activation in 
citrated plasma.  Combined with known biochemical mechanism of FVII auto 
activation in the presence of a charged surface, this work substantiates the 
contributing material properties which influence this activation.   
The clinical research conducted clearly indicates that positive electrostatic charge 
and cross-link density, i.e. mechanical stiffness, are key factors in determining the 
ability of a polymer hydrogel to promote or enhance hemostasis.    It was determined 
that although hydrogels containing higher positive electrostatic charge with low 
cross-density delayed or inhibited fibrin formation (blood coagulation activation) they 
were effective at enhancing and promoting platelet plug formation in the presence of 
an activator.  On the other hand, although stiffer hydrogels, i.e. hydrogels containing 
higher cross-link densities, were capable of expediting the onset of coagulation 
activation and subsequent fibrin formation they were ineffective at inducing the 
formation of an effective hemostatic plug. 
In vivo animal experimentation confirmed the ability a specific charged polymer 
hydrogel to induce hemostasis in a clinically relevant model.  Furthermore, this 
experimentation indicated that positive electrostatic charge and cross-link density 
were key material parameters which affect the hemostasis in vivo.  Histological 




of platelets and erythrocytes stabilized by fibrin generated from the surface of the 
particles. 
This research has contributed to a better understanding of the activation 
mechanism of coagulation proteins, specifically FVII, which is crucial to the design 
of a system capable of safely and effectively enhancing this activation.  From a 
clinical viewpoint this research provides a clear correlation between specific material 
properties of a synthetic polymer-based material and corresponding influence on the 
body’s clotting response.  Understanding how specific coagulation components 
interact with material chemistries is vital to the development of any engineered blood 
contacting materials including but not limited to artificial organ coatings, in vivo 
therapeutic delivery systems, and stents.  In conclusion, it is the hope of the author 
that this research lays the foundation for the development of future biomaterials 
capable of influencing or manipulating blood-based physiological processes which 
will help millions of people in the future. 
 
4.2 Future Work 
 
Future work will focus on developing a better understanding of the material 
properties which affect hemostasis in vivo.  Experiments utilizing unadulterated, 
lacking anticoagulation, human and sheep blood will be conducted to determine the 
influences that specific material properties have on the activation of coagulation 
factors.  Further clinical diagnostic experimentation, including platelet aggregometry 




determinants involved with platelet activation, aggregation, and eventual plug 
formation. 
In terms of material synthesis, efforts will be made to alter the chemistry of the 
synthesized polymer hydrogel in order to ensure that it will undergo safe and rapid 
degradation within the body.  Rapid degradation within the wound site is vital to 
preventing the material from interfering with the body’s natural healing process.  
Additionally, research will focus on enhancing the tissue adhesiveness of the polymer 
hydrogel so that the material is better able to seal the wound site. 
Finally, research will be conducted in order to investigate the ability of the 
polymer hydrogel to systematically deliver a therapeutic in a controlled manner to the 
injured site.  A material capable of inducing effective hemostasis while 
simultaneously delivering a therapeutic to the wound site would have incredible 
potential in the healthcare field.   
Overall, future research will focus on developing a better understanding of the 
material properties which affect the body’s blood clotting response.   A better 
understanding of the interactions that occur between engineered materials and the 
body’s physiologic blood clotting response is the key to the development of next-
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